Skip to main content
SP5007,711.76-0.25%DOW53,559.99-0.02%NASDAQ26,402.42-0.52%BTC$77,493.00-3.14%ETH$2,432.55-2.84%GOLD$4,507.80-3.35%OIL$83.47-0.07%
Smart Investors Daily
Sign InSign Up Free
VA

NASDAQ · VANI

Vivani Medical, Inc.

Healthcare · Medical - Devices

$1.40

Up+$0.02 (+1.43%)

Updated Aug 28, 2026, 8:32 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
82.71M
P/E ratio
-3.21
Dividend yield
0.00%
52-week range
$0.92 – $1.66
Volume
86.72K
Avg. volume
301.05K

Price performance

VANI price history

1M range · 21 trading sessions · Daily adjusted prices

VANI closed at $1.40 after 21 trading sessions, up 7.69% for the selected period.

Last close
$1.40
Period change
+7.69%
Period low
$1.28
Period high
$1.45
Daily close
View OHLC price history
VANI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 27, 2026$1.42$1.42$1.395$1.4086.72K
Aug 26, 2026$1.43$1.45$1.3701$1.415215.68K
Aug 25, 2026$1.38$1.42$1.34$1.42200.72K
Aug 24, 2026$1.40$1.415$1.3428$1.38174.44K
Aug 21, 2026$1.44$1.44$1.365$1.38104.74K
Aug 20, 2026$1.36$1.4229$1.36$1.41108.34K
Aug 19, 2026$1.46$1.53$1.301$1.39789.16K
Aug 18, 2026$1.35$1.45$1.335$1.45349.75K
Aug 17, 2026$1.40$1.40$1.35$1.35124.85K
Aug 14, 2026$1.34$1.42$1.335$1.40114.35K
Aug 13, 2026$1.39$1.40$1.31$1.34197.18K
Aug 12, 2026$1.40$1.43$1.34$1.37155.36K
Aug 11, 2026$1.41$1.41$1.38$1.3954.57K
Aug 10, 2026$1.44$1.44$1.35$1.41194.36K
Aug 7, 2026$1.43$1.44$1.38$1.41195.69K
Aug 6, 2026$1.38$1.40$1.36$1.3653.04K
Aug 5, 2026$1.43$1.43$1.35$1.3887.51K
Aug 4, 2026$1.34$1.42$1.33$1.40157.41K
Aug 3, 2026$1.29$1.37$1.2747$1.33146.16K
Jul 31, 2026$1.32$1.32$1.28$1.2834.54K
Jul 30, 2026$1.28$1.32$1.27$1.3088.99K

Latest VANI news

The latest Smart Investors Daily articles mentioning VANI.

Stock researchCompany · Overview

VANI research

Overview

Company profile and research snapshot.

Company profile

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VANI recent ratings
DateFirmRatingTarget
Jun 23, 2026Lake StreetBuy—
Mar 31, 2026HC Wainwright & Co.Buy—
Sep 2, 2025HC Wainwright & Co.Buy—
May 19, 2025HC Wainwright & Co.Buy—
Apr 16, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 13, 2026

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT an

Benzinga · Aug 13, 2026

Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from

Yahoo · Aug 6, 2026

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize the safety, tolerability, and pharmacokinetics of NPM-139 including a Wegovy® (semaglutide injection) group. Top-line data from the 20-participant trial is expected in November of 2026. ALAMEDA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) today an

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By